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Background: Hyponatremia is a common electrolyte disorder. Multiple organizations have published guidance
documents to assist clinicians in managing hyponatremia. We aimed to explore the scope, content, and
consistency of these documents.
Methods: We searched MEDLINE, EMBASE, and websites of guideline organizations and professional societies to
September 2014 without language restriction for Clinical Practice Guidelines (defined as any document providing
guidance informed by systematic literature review) and Consensus Statements (any other guidance document)
developed specifically to guide differential diagnosis or treatment of hyponatremia. Four reviewers appraised guideline
quality using the 23-item AGREE II instrument, which rates reporting of the guidance development process across six
domains: scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and
editorial independence. Total scores were calculated as standardized averages by domain.
Results: We found ten guidance documents; five clinical practice guidelines and five consensus statements. Overall,
quality was mixed: two clinical practice guidelines attained an average score of >50% for all of the domains, three
rated the evidence in a systematic way and two graded strength of the recommendations. All five consensus
statements received AGREE scores below 60% for each of the specific domains.
The guidance documents varied widely in scope. All dealt with therapy and seven included recommendations on
diagnosis, using serum osmolality to confirm hypotonic hyponatremia, and volume status, urinary sodium concentration,
and urinary osmolality for further classification of the hyponatremia. They differed, however, in classification thresholds,
what additional tests to consider, and when to initiate diagnostic work-up. Eight guidance documents advocated
hypertonic NaCl in severely symptomatic, acute onset (<48 h) hyponatremia. In chronic (>48 h) or asymptomatic cases,
recommended treatments were NaCl 0.9%, fluid restriction, and cause-specific therapy for hypovolemic, euvolemic,
and hypervolemic hyponatremia, respectively. Eight guidance documents recommended limits for speed of increase
of sodium concentration, but these varied between 8 and 12 mmol/L per 24 h. Inconsistencies also existed in the
recommended dose of NaCl, its initial infusion speed, and which second line interventions to consider.
Conclusions: Current guidance documents on the assessment and treatment of hyponatremia vary in methodological
rigor and recommendations are not always consistent.
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Hyponatremia is the most common electrolyte disorder in
clinical medicine; it represents an excess of water relative
to total body solute [1]. Hyponatremia usually results from
the intake and subsequent retention of electrolyte-free
water in response to true hypovolemia due to gastro-
intestinal solute loss or malnutrition; decreased effective
circulating volume due to heart failure or liver cirrhosis;
or non-osmotic vasopressin activity due to malignancies,
infections, medications, pain, or stress [2]. When defined
as a serum sodium concentration below 135 mmol/L,
hyponatremia occurs in up to 8% of the general popula-
tion and in up to 60% of hospitalized patients [2,3]. Acute
profound hyponatremia can cause brain edema, but also
chronic mild hyponatremia is associated with poor health
outcomes. Even when comorbid conditions are taken
into account, people with a mildly decreased serum
sodium concentration have a 30% higher risk of death and
are hospitalized 14% longer relative to those without
hyponatremia [2,4].
Despite the frequency and severity of some of the
associated complications, research suggests hyponatre-
mia is often neglected by clinicians [5]. If acquired in
hospital, it may take days before the electrolyte disorder
is investigated, potentially allowing a further decrease in
serum sodium concentration and exposing patients to
the dangers of profound hyponatremia. When efforts are
made to explore the underlying cause, clinicians use widely
different strategies for differential diagnosis, testing is often
inadequate and misclassification of the hyponatremia fre-
quently occurs [6,7].
Hyponatremia may be managed clinically by different
specialists, such as endocrinologists, nephrologists, geri-
atricians, or intensivists, and, accordingly, management
strategies often vary [5]. Although probably related to
variation in awareness, differences in expert opinion on
whom and how to treat only add to the confusion over
optimal management. For instance, although experts agree
that acute symptomatic hyponatremia should be treated
with hypertonic saline, the optimal concentrations and
methods for determining initial infusion speeds are
debated [1]. In addition, the risk of osmotic demyelination
syndrome after rapid correction of hyponatremia has
fuelled intense debate among experts on whether compli-
cations of untreated hyponatremia or complications of
treatment pose the greatest risk [8]. As different specialist
physicians deal with hyponatremia, consultation of differ-
ent information and guidance sources may add to the
variability in treatment seen in clinical practice today.
Clinical practice guidelines and consensus statements
provide recommendations to help evidence-based prac-
tice by suggesting the most appropriate diagnostic tests
and the most appropriate treatments. Over the years,
multiple organizations have developed recommendationsto assist clinicians in the management of hyponatremia.
To be reliable, these recommendations must be based
on a systematic review of the evidence, and have a trans-
parent and multidisciplinary development process [9].
Inconsistencies between recommendations may arise
from failing to meet development standards and can
only add to unwarranted variability in management. In
this study, we aimed to explore the scope, content, and
consistency of the existing guidance documents on the
diagnosis and management of hyponatremia in adults
and children.Methods
Criteria for selection of studies
We included evidence-based clinical practice guidelines
and consensus statements on the diagnosis and treatment
of hyponatremia. We defined clinical practice guidelines
as statements that included recommendations intended to
optimize patient care informed by a systematic review of
evidence and an assessment of the benefits and harms
of alternative care options [9]. We defined consensus
statements as documents containing clinically relevant
suggestions or recommendations based on the col-
lective opinion of an expert panel [9]. We included all
publications independent of language. We excluded
guidelines related to the prevention of hyponatremia
as well as guidelines relevant to conditions associated
with hyponatremia if they were not specifically designed
to address hyponatremia. Hence, we excluded guidelines
targeting treatment of heart failure, cirrhosis, and cancer
unless they were developed with a focus on hyponatremia
as a complication. Finally, we also excluded draft unpub-
lished guidelines, conference or discussion papers, personal
opinions, and obsolete guidelines replaced by updated rec-
ommendations from the same organization.Search methods for guidelines and consensus statements
We searched MEDLINE (1946 to September Week 1,
2014) and EMBASE (1980 to September 2014), combining
vocabulary terms and text words for hyponatremia with
terms related to clinical practice guidelines and consensus
statements. We also searched guideline databases and
websites of organizations as well as of selected profes-
sional specialist societies in nephrology, endocrinology,
and intensive care medicine. A list of the databases and
websites along with the full search strategies are outlined
in Additional file 1. EN and JV independently screened
the titles and abstracts and discarded those that did not
meet the inclusion criteria. Full texts for potentially
relevant guidelines or consensus statements were retrieved
and examined for eligibility. Both the initial screening and
subsequent full-paper assessment stage were completed
using Early Review Organizing Software [10].
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We developed a draft data extraction form which was
piloted and modified as necessary. The extracted data
included document characteristics (e.g., year of publi-
cation, country/region, development team, funding
organization), recommendations related to the diagno-
sis and assessment of hyponatremia, and recommen-
dations related to the treatment of hyponatremia. EN
and JV extracted all data using the standardized data
extraction form (Additional file 2) and resolved dis-
crepancies by consensus.
Appraisal of guidelines and consensus statements
Four reviewers independently assessed methodological
quality using the Appraisal of Guidelines for Research and
Evaluation (AGREE II) instrument [11]. AGREE II is an
internationally validated, rigorously developed 23-item tool
used to evaluate six domains of guideline development:
scope and purpose, stakeholder involvement, rigor of de-
velopment, clarity of presentation, applicability, and editor-
ial independence [12] (Additional file 3). The AGREE tool
has also been used to assess consensus statements [13,14].
The reviewers rated each item on a Likert scale from 1
(? Strongly Disagree? ) to 7 (? Strongly Agree? ). We calculated
a total score for each domain by summing up all the scores
of the individual items in a domain for each reviewer
and then standardizing this total as a percentage of the
maximum possible score for that domain, calculated as
follows [12]:
Obtained score − Minimum possible score
Maximum possible score − Minimum possible score
 100%
The minimum possible score for each domain equaled
the number of questions multiplied by the number of
reviewers, multiplied by 1 (strongly disagree). The max-
imum score for a domain equaled the number of ques-
tions multiplied by the number of reviewers, multiplied
by 7 (strongly agree). To ensure standardization of each
reviewer ? s approach, all reviewers completed the online
training tutorial [15] before starting the project.
In a consensus meeting among the reviewers, we dis-
cussed every item for which scores differed by more than
1 point (e.g., 1 versus 3) on the original 7-point scale.
Reviewers in turn explained the rationale for their score
and had the opportunity to revise their score when they
considered this appropriate. We audiotaped the consensus
meeting to reliably record the underlying reasons for
changing scores.
Synthesis of guideline recommendations
We conducted a textual descriptive synthesis to analyze the
scope, content, and consistency of the included recommen-
dations. EN inductively coded the text manually to identifydomains covered by the guidelines. These were cross-
tabulated with the guidelines and recommendations were
inserted into the corresponding cell. For each domain, we
compared guideline recommendations to identify similar-
ities and discrepancies. Consistent with the scope of this
review, we only tabulated the information on diagnosis
and treatment of hyponatremia.
Results
Search results
We identified 1,402 citations, of which we excluded 1,367
after screening titles and abstracts because they did not
meet our eligibility criteria (Figure 1). We assessed the full
text of the remaining 39 citations and excluded 29 because
they were not related to the diagnosis or treatment of
hyponatremia, were not clinical practice guidelines or con-
sensus statements, or were guidelines replaced by an
updated version (Additional file 4). Ultimately, we included
five clinical practice guidelines [16-20] and five consensus
statements [21-25]. Six of these documents were retrieved
through searching the medical databases [18-20,23-25], the
other four through the search of guideline databases and
professional society websites [16,17,21,22].
Table 1 shows the general characteristics of the included
clinical practice guidelines and consensus statements. Eight
national or regional organizations from the Netherlands
[16], United Kingdom [17], Northern Ireland [22], Spain
[23,25], United States [18,19], Australia [21], and two inter-
national groups [20,24] published these guidance docu-
ments between 2004 and 2014. One document specifically
covered children [21], the others primarily targeted adults.
Six groups reported undertaking a systematic review and
appraisal of the evidence [16-20,24]. Only three were ex-
plicit about the level of evidence that underpinned their
recommendations [16,18,20], and only two graded the
strength of the guidance recommendations themselves
[18,20]. Five guidance documents covered hyponatremia
broadly; one specifically covered it in the setting of pri-
mary care, one in liver cirrhosis, one in neurosurgery, and
one in exercise-associated hyponatremia. Three included
treatment only [23-25], the seven others covered diagnosis
as well [16-22]. Two groups reported funding by a govern-
mental institution [16,22], one by the professional soci-
eties they represented [20]; the others did not report their
funding sources [17-19,21,23-25].
Appraisal of guidelines and consensus statements
Figure 2 shows the standardized domain scores for each
guideline for each of the six quality domains assessed
with the AGREE II tool (See Additional file 5 for mean
individual scores per item across reviewers). The overall
quality of reporting of the guideline development process
as assessed by AGREE varied widely both between guid-
ance documents across domains and within guidance
Figure 1 Flow diagram of the identification process for clinical practice guidelines and consensus statements on hyponatremia.
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opers reported the details of the guideline development
process only to a limited extent. Most had average scores
below 50% in four to six of the six AGREE II domains
[17,19,21-25], only two received an average >50% on all
six [16,20].
Guidelines received the highest scores for scope and
purpose (median 62%; range 28% to 92%) and clarity of
presentation (median 47%; range 27% to 75%), and low-
est scores for applicability (median 19%; range 10% to
68%) and editorial independence (median 19%; range 2%
to 79%).
Initial appraisal results differed more than one point
on the Likert scale between two or more reviewers for
143/230 items (62%). The majority of discrepancies were
found in the domain ? Clarity of Presentation ?, with 90%
of items differing more than one point. Group discussion
resulted in 287/920 (31%) of individual entries being
changed. Finally, no scores differed more than two
points and for 82% of items, scores were the same orwithin one point of each other. Major reasons for chan-
ging an entry were a change of own opinion after clarifi-
cation of the opinion of other reviewers during the
group discussion (180/920 entries; 20% entries); aiming
for consistency between entries given same available data
(39/920; 4%); re-evaluation of the score in light of a
noted comment during the appraisal process (30/920;
3%); correction for available data that were overlooked
during the initial appraisal (22/920; 2%); misinterpret-
ation of the question during the initial appraisal (6/920;
0.7%); adjusting for arbitrary scoring of items that were
felt to be inapplicable for some reason (3/920; 0.3%);
adjusting for inconsistent approach to deal with the
assumption that a criterion was fulfilled even if this was
not clearly mentioned (4/920; 0.4%); and data entry error
(3/920, 0.3%). Overall, this resulted in 29/60 (48%) of
standardized domain scores being downgraded by a max-
imum of 10% and 10/60 (17%) of standardized domain
scores being upgraded with a maximum of 10%; the
remaining 35% remained unchanged.
Table 1 Characteristics of included guidelines and consensus statements
Developer Year Country Funding
source
Target
population
Target
users
Guideline
writers
Guideline
review
Guideline
update
Methods
support
Evidence
base
Europe
NIV 2012 Netherlands Government
funding
Adults with
hyponatremia
Clinicians,
Internists
Multidisciplinary
internists,
epidemiologist
Dutch Association
of Internists (NIV),
expert peer review
In case of
breakthrough
changes in
diagnosis or
treatment
PROVA ? company
specialized in
Evidence Based
Guideline
Development
Systematic
literature
review
NHS 2011 UK NS Adults with
hyponatremia in
primary care
Primary care
professionals
within NHS
NS NS Planned
in 2015
NS Systematic
literature
review
GAIN* 2010 Northern
Ireland
Government
funding
Adults with
hyponatremia
NS Multidisciplinary
anesthetists, clinical
chemist, nephrologist
NS 3 years NS NS
AEEH* 2003-
2004
Spain NS Patients with cirrhosis NS Gastroenterologists NS NS NS NS
EHN* 2013 Spain NS Hospitalized patients
with SIADH
NS Multidisciplinary
endocrinologists,
nephrologists, internists,
hospital pharmacist
NS NS NS Consensus
statements
ERBP/ESE/
ESICM
2014 Europe Unrestricted
grant from
participating
societies
Adults with
hyponatremia
Health care
professionals
dealing with
hyponatremia
Multidisciplinary
nephrologists,
endocrinologists,
general internists,
critical care physicians
External review by
KHA-CARI, ESA, and
members ERA-EDTA
5 years or
earlier in
case of new
evidence
requiring
changes
ERBP methods
support team
Systematic
literature
review
North
America
UF 2008-
2009
USA NS Neurosurgery patients
with hyponatremia
NS Multidisciplinary
neurosurgeons, nurse
practitioners, nephrologists,
critical care physician,
endocrinologist,
pharmacist, nurses
NS NS NS Systematic
literature
review
HEP 2013 USA Funding
Unrestricted
educational
grant from
pharmaceutical
company
Patients with
hyponatremia
NS Endocrinologist,
nephrologists
NS NS NS Systematic
literature
review
Australia
RCHM* 2012 Australia NS Children NS NS External review
within the hospital
where appropriate?
12 to
24 months
NS NS
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Table 1 Characteristics of included guidelines and consensus statements (Continued)
International
EAH- ICD* 2007 USA, Canada,
UK, Switzer-land,
Canada, South
Africa, New
Zealand, Australia
No commercial
sponsorship?
People with
exercise-associated
hyponatremia
Medical
personnel,
athletes,
greater public
Multidisciplinary
endocrinologist,
epidemiologist,
nephrologists,
emergency medicine
physician, general
practitioner, internist,
sports physicians,
exercise physiologists
NS NS NS Systematic
literature
review
NIV, Nederlandse Internisten Vereniging [16]; NHS, National Health Service [17]; GAIN, Guidelines and Audit Implementation Network [22]; AEEH, La Asociaci?n Espa?ola para el Estudio del H?gado [ 23]; EHN, European
Hyponatremia Network [25]; ERBP, European Renal Best Practice; ESE, European Society of Endocrinology; ESICM, European Society of Intensive Care Medicine [20]; UF, University of Florida [18]; HEP, Hyponatremia
Expert Panel [19]; RCH Melbourne, the Royal Children ? s Hospital Melbourne [21]; EAH-ICD, International Exercise-Associated Hyponatremia Consensus Development Conference [24]; [Na], Serum sodium concentration;
NS, Not stated; KHA-CARI, Kidney Health Australia, Caring for Australasians with Renal Impairment; ESA, Endocrine Society of Australia; ERA-EDTA, European Renal Association; European Dialysis and Transplant
Association; *Classified as consensus statement.
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Figure 2 Guideline assessment according to the appraisal of guideline for research and evaluation (AGREE II) instrument. NIV, Nederlandse
Internisten Vereniging [16]; NHS, National Health Service [17]; GAIN, Guidelines and Audit Implementation Network [22]; AEEH, La Asociaci?n Espa? ola
para el Estudio del H?gado [23]; ERBP, European Renal Best Practice; ESE, European Society of Endocrinology; ESICM, European Society of Intensive
Care Medicine [20]; UF, University of Florida [18]; HEP, Hyponatremia Expert Panel [19]; RCH Melbourne, the Royal Children? s Hospital Melbourne [21];
EAH-ICD, International Exercise-Associated Hyponatremia Consensus Development Conference [15]; *Classified as consensus statement. Note: items
were originally scored on a Likert scale of 1 [Strongly Disagree] to 7 [Strongly Agree]. The numerical scores presented for each domain are a summary
of individual item scores by each reviewer.
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The included guidance documents addressed three major
themes: diagnosis, treatment, and speed of correction.Approaches to diagnostic strategies for hyponatremia
Seven guidance documents covered diagnosis and differen-
tial diagnosis of hyponatremia [16-22]. Table 2 shows the
key recommendations. The key areas addressed included
the threshold for initiating diagnostic workup, confirmation
and classification of hypotonic hyponatremia, and identifi-
cation of the underlying disorder.Guidance documents differed somewhat in their recom-
mended threshold for starting diagnostic assessment. Six
recommended starting diagnostic assessment when the
serum sodium concentration dropped below 135 mmol/L
[17,19-23] and to confirm hypotonicity through a measured
serum or plasma osmolality <275 to 285 mOsm/kg
[16-20,22]. Two others set lower thresholds of serum so-
dium concentration at <131 mmol/L [18] and <130 mmol/L
[23]. Six guidance documents advised classifying hypotonic
hyponatremia into categories of hypovolemia, euvolemia,
and hypervolemia to aid differential diagnosis and guide
treatment [16-22]. Most guidance documents recom-
Table 2 Summary of recommendations for approaches to diagnosis of hyponatremia by included guidance documents
Guideline Organization/Society
Criteria/Categories NIV [16] NHS [17] GAIN [22] AEEH [23] EHN [25] ERBP/ESE/
ESICM [20]
UF [18] HEP [19] RCHM [21] EAH-ICD
[24]
Threshold workup [Na] <135 mmol/L <135 mmol/L <135 mmol/L <130 mmol/L <135 mmol/L <135 mmol/L <131 mmol/L <135 mmol/L <135 mmol/L
Confirming hypotonic
hyponatremia
Serum osmolality
<275 mOsm/kg
Plasma osmolality
<280 mOsm/kg
Serum osmolality
<275 mOsm/kg
Plasma osmolality
<275 mOsm/kg
Serum osmolality
<275 mOsm/kg
Serum osmolality
<285 mOsm/kg
Plasma osmolality
<280 mOsm/kg
Serum
osmolality
threshold
not stated
How to classify
hypotonic hyponatremia
to aid identification of
underlying cause
Volume status/
hydration state/
extracellular fluid
status
Clinical
evaluation
Physical
examination/clinical
signs of dehydration
or edema
Physical
examination/clinical
signs of dehydration
or edema
Physical
examination/
clinical signs of
low circulating
volume
Physical
examination/
clinical signs of
dehydration
or edema
Physical
examination/
laboratory
measurements
Physical
examination/
laboratory
measurements
To assess
but method
not stated
Urinary [Na]/Threshold 30 mmol/L Spot urine:
20? 30 mmol/L
15 mmol/L 40 mmol/L 30 mmol/L 25 mmol/L Spot urine:
20? 30 mmol/L
No threshold
stated
Urinary osmolality/
Threshold
100 mOsm/kg 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg No threshold
stated
How to identify the
underlying disorder
History Medications Medications Diuretic use
Fluid intake Recently prescribed
intravenous fluids
Nocturnal polyuria Vomiting/diarrhea
Lab tests
Serum potassium
concentration
+ + +
Serum chloride
concentration
+ +
Serum urea
concentration
+/? + +/? +/? +
Serum creatinine
concentration
+ + +/? +/? +
Serum glucose
concentration
+ + +/? + +
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Table 2 Summary of recommendations for approaches to diagnosis of hyponatremia by included guidance documents (Continued)
Urinary potassium
concentration
+ +
Renal tests +
Liver tests + +/ ?
Urinary protein +/?
Thyroid function
tests
+/? +/? +/? +/?
Adrenal function
tests
+/? +/? +/? +/?
Serum protein
electrophoresis
+/?
Urine protein
electrophoresis
+/?
Fractional sodium
excretion
+/?
Serum uric acid
concentration
+/? +/? + +/?
Fractional uric acid
concentration
+/?
Fractional excretion
urea
+/?
Urinary chloride
concentration
+/? + +/?
Molar weight urine +/ ?
Serum bicarbonate
concentration
+/?
Hematocrit +/?
[Na], Serum sodium concentration; +, always; +/ ? , If clinically indicated/sometimes useful.
NIV, Nederlandse Internisten Vereniging [16]; NHS, National Health Service [17]; GAIN, Guidelines and Audit Implementation Network [22]; AEEH, La Asociaci?n Espa?ola para el Estudio del H?gado [ 23]; EHN, European
Hyponatremia Network [25]; ERBP, European Renal Best Practice; ESE, European Society of Endocrinology; ESICM, European Society of Intensive Care Medicine [20]; UF, University of Florida [18]; HEP, Hyponatremia
Expert Panel [19]; RCH Melbourne, the Royal Children ? s Hospital Melbourne [21]; EAH-ICD, International Exercise-Associated Hyponatremia Consensus Development Conference [24].
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http://www.biomedcentral.com/1741-7015/12/231mended a clinical assessment of hydration status and a
urinary sodium concentration as well as a urinary osmo-
lality measurement, although specific criteria, thresholds,
and algorithms differed.
Most guidance documents proposed additional labora-
tory tests that could be of value to identify the underlying
disorder, but they varied substantially regarding which
tests to use in what situation and which reference values
to use. Only two explicitly recommended taking a history
of drug intake and symptoms as part of the assessment
[17,22]. Four presented an algorithm to guide differential
diagnosis [16,18,20,22].
Approaches to treatment for hyponatremia
Table 3 shows the recommendations for the medical man-
agement of hyponatremia. Guidance documents distin-
guished treatment scenarios based on whether patients
had severe symptoms [17-22,24,25] or whether the hypo-
natremia was acute (48 h) or chronic [16]. All but one
discussed treatment in the setting of severe symptoms and
recommended infusion of hypertonic saline, usually speci-
fied as having a concentration of 3% [17,19-21,24,25]. One
suggested using a formula to guide the infusion speed of a
continuous infusion [16], five others recommended giving
a fixed dose [19,20,22,24,25], or a dose adjusted to body
weight [21,25] with repeated serum sodium concentration
measurements to check progression [16,20-22,25].
Patients without symptoms of hyponatremia were
assumed to have chronic onset hyponatremia, and
treatment suggestions were mostly dependent on the
classification hypovolemic, euvolemic, or hypervolemic.
Only three guidance documents specifically advised treat-
ing the underlying condition [19,22]. Seven suggested
0.9% saline in hypovolemia [16-22], with infusion speeds
calculated with Adrogu?-Madias [22], until restoration of
blood pressure [17,19] or until nasogastric rehydration
could start [21].
For euvolemic asymptomatic hyponatremia, the majority
recommended fluid restriction as the first-line treatment
[16-25]. Five guidance documents proposed a number of
other interventions as second-line treatments including
loop diuretics [16,18,20,25], demeclocycline [16-19], urea
[16,19,20,25], vasopressin receptor antagonists [16,17,25],
or lithium [18]. One guideline specifically recommended
against vasopressin receptor antagonists in case of a serum
sodium concentration <125 mmol/L [20].
For hypervolemic asymptomatic hyponatremia, seven
guidance documents recommended fluid restriction as
the first-line treatment [16,17,19-23] (Table 3). Three guid-
ance documents advocated concomitant salt restriction,
without clear dose recommendations [17,19,22], and one to
avoid hypotonic infusion solution [21]. Three additionally
proposed loop diuretics [16,17,19] and three others gener-
ally stated to treat the underlying disease [17,20,22],whereas one advised to consider stopping diuretics [23].
One guideline additionally proposed demeclocycline and
two proposed vasopressin receptor antagonists as a second-
line treatment for refractory hyponatremia [17,19], whereas
one guideline specifically recommended against both deme-
clocycline and vasopressin receptor antagonists [20].
Targets and limits of speed of correction
Table 4 shows the key recommendations. The key areas
include targets and limits for increase in serum sodium
concentration.
Seven guidance documents provided targets or aims for
the increase in serum sodium concentration in case of
symptomatic and/or acute hyponatremia [16,17,19-22,25].
Seven guidance documents provided limits for the
increase in serum sodium concentration that should
not be surpassed [16-22,25]. Five did so independent of
symptoms [16,18,20,22,25]. Limits usually varied between
8 to 12 mmol/L during the first 24 hours [16-22,25] and
18 mmol/L during the first 48 hours [16,17,19,20,25],
irrespective of whether hyponatremia was acute or
chronic [16,17,20,25]. Three guidance documents set a
stricter limit of <8 mmol/L during the first 24 hours in
cases where the patient was believed to be high risk for
developing osmotic demyelination syndrome [16,19,25].
Four discussed what to do in case of overcorrection, i.e.,
to stop current treatment and to consider re-lowering
serum sodium concentration by starting hypotonic infu-
sion and administering 1 to 4 μg desmopressin every 6 to
8 hours [16,19,20,25].
Discussion
We found five clinical practice guidelines and five con-
sensus statements covering the diagnostic approach to
and treatment of hyponatremia. Although most used
serum osmolality, volume status, urinary sodium, and
urinary osmolality to guide differential diagnosis, they
differed in classification thresholds, what additional tests
to consider, and when to initiate diagnostic work-up.
Most advocated hypertonic NaCl in severely symptom-
atic, acute onset hyponatremia and NaCl 0.9%, fluid
restriction, and cause-specific therapy for hypovolemic,
euvolemic, and hypervolemic hyponatremia, respectively.
However, they somewhat differed in the limits for speed
of increase in serum sodium concentration and which
specific medications to use. The reasons for offering
different recommendations are undoubtedly multifac-
torial. They may in part be explained by the fact that
recommendations were issued by organizations differing
in context and scope. It is also very likely that some
variability in guidance arose through limitations in the
evidence available for guideline developers to base their
recommendations on [8]. In the most recent guideline
on diagnosis and treatment of hyponatremia, 98% of the
Table 3 Summary of recommendations for approaches to treatments for hyponatremia by included guidance documents
Guideline Organization/Societies
Criteria/
categories
NIV [16] NHS [17] GAIN [22] AEEH [23] EHN [25] ERBP/ESE/
ESICM [20]
UF [18] HEP [19] RCHM [21] EAH-ICD
[24]
Symptoms
Acute Onset
(<48 h)
NaCl >1%
Infusion speed
may be guided by
Adrogu?-Madias
NaCl 3% NaCl 2.7%
200 mL over
30 min
NaCl 3% 100 mL/
10 min up to
3? or infused at
0.5? 2 mL/kg/h
NaCl 3% 150 mL/
20 min up to 4?
NaCl >1% NaCl 3% 100 mL/
10 min up to
3? or infused at
0.5? 2 mL/kg/h
NaCl 3%
4 mL/kg
over 30 min
NaCl 3%
100 mL
bolus
Hypovolemia NaCl 0.9% until
blood pressure
restored
Euvolemia Fluid restriction No
hypotonic
fluids
Stop offending
drugs
Stop hypotonic
fluids
Hypervolemia Furosemide Furosemide
Chronic onset
(>48 h)
NaCl >1% Infusion
speed calculation
may be guided by
Adrogu?-Madias
NaCl 3% Only if severe
symptoms NaCl 2.7%
200 mL over 30 min
infusion speed by
may be guided
Adrogu?-Madias
NaCl 3% 100 mL/
10 min up to
3? or infused at
0.5? 2 mL/kg/h
NaCl 3% 150 mL/
20 min up to 4?
NaCl >1% NaCl 3% 100 mL/
10 min up to 3?
or infused at
0.5-2 mL/kg/h
Hypovolemia NaCl 0.9% 1 L over
2? 4 h infusion speed
may be guided by
Adrogu?-Madias
NaCl 0.9% until
blood pressure
restored
Euvolemia Fluid restriction
Stop offending
medications
Stop hypotonic
fluids
Hypervolemia Fluid restriction Furosemide
Salt restriction
No symptoms
Acute onset
(<48 h)
NaCl >1%
Infusion speed by
Adrogu?-Madias
Treat underlying
condition
Stop offending fluids
and medications,
treat underlying
Treat underlying
condition
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Table 3 Summary of recommendations for approaches to treatments for hyponatremia by included guidance documents (Continued)
condition NaCl
3% 150 mL/20 min
Chronic
onset (>48 h)
Treat underlying
condition
Treat underlying
condition
Stop non-essential
fluids Stop offending
medications Treat
underlying condition
Treat underlying
condition
Hypovolemia NaCl 0.9% NaCl 0.9% until
blood pressure
restored
NaCl 0.9%
infusion speed
may be guided by
Adrogu?-Madias
NaCl 0.9% or
balanced crystalloid
0.5? 1 mL/kg/h
NaCl 0.9% NaCl 0.9% until
blood pressure
restored
Nasogastric
rehydration
NaCl tablets No VPA NaCl 0.9%
Euvolemia Fluid restriction,
dose dependent
on serum and
urinary electrolytes
Fluid restriction,
500? 1,000 mL/d
Fluid restriction Fluid restriction
<500? 1,000 mL/d
Fluid restriction Fluid restriction Fluid restriction
500 mL below
average daily
urine output
Fluid restriction,
no hypotonic
fluids
No salt
restriction
Salt restriction Salt 5 ? 8 g/d No salt restriction
Loop diuretics Furosemide
20? 60 mg/d +
oral NaCl
Loop diuretics,
low dose +
oral NaCl
Diuretics
Demeclocycline Demeclocycline No demeclocycline Demeclocycline Demeclocycline,
600? 1,200 mg/d
Urea Urea 30 g/d Urea, 0.25? 0.5 g/kg/d Urea Urea, 15? 60 g/d
Vasopressin
receptor
antagonist
Vasopressin
receptor antagonist
Tolvaptan
15? 60 mg/d
No vasopressin
receptor antagonists
Hypervolemia Treat underlying
condition
Fluid restriction,
dose dependent
on serum and
urinary electrolytes
Fluid restriction Fluid restriction Fluid restriction
<1,000 mL/d
Fluid restriction Fluid restriction,
<insensible losses +
urine output
Fluid restriction
Loop diuretics Salt restriction Salt restriction No NaCl >0.9% Salt restriction
Demeclocycline Stop
diuretics
No demeclocycline Possibly vasopressin
receptor antagonist
Vasopressin
receptor
antagonist
No vasopressin
receptor antagonist
NIV, Nederlandse Internisten Vereniging [16]; NHS, National Health Service [17]; GAIN, Guidelines and Audit Implementation Network [22]; AEEH, La Asociaci?n Espa?ola para el Estudio del H?gado [ 23]; EHN, European
Hyponatremia Network [25]; ERBP, European Renal Best Practice; ESE, European Society of Endocrinology; ESICM, European Society of Intensive Care Medicine [20]; UF, University of Florida [18]; HEP, Hyponatremia
Expert Panel [19]; RCH Melbourne, the Royal Children ? s Hospital Melbourne [21]; EAH-ICD, International Exercise-Associated Hyponatremia Consensus Development Conference [24].
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Table 4 Summary of recommendations for targets and limits for speed of correction of hyponatremia by included guidance documents
Guideline Organization/Societies
Criteria/
categories
NIV NHS GAIN AEEH EHN ERBP/ESE/ESICM UF HEP RCHM EAH-
ICD
[16] [17] [22] [23] [25] [20] [18] [19] [21] [24]
Targets [Na]
increase
Symptoms Independent
of symptoms
If symptoms If symptoms If symptoms If symptoms If symptoms Until seizures resolve
or [Na] >125 mmol/L
Acute onset
(<48 h)
1? 2 mmol/L/h
initially
Until [Na]
>120 mmol/L
independent
of onset
1? 2 mmol/L/h
first 2? 3 h
1? 6 mmol/L first 2 h 5 mmol/L first h 4? 6 mmol/L
urgently
Independent of onset
Chronic onset
(>48 h)
0.5 ? 1 mmol/
L/h first 2? 3 h
1? 6 mmol/L first 2 h 5 mmol/L first h If seizures or coma
4? 6 mmol/L urgently,
otherwise 4 ? 6 mmol/L
per 24 h
Limits [Na]
increase
Symptoms Independent
of symptoms
If no symptoms Independent
of symptoms
Independent of
symptoms
Independent
of symptoms
Independent
of symptoms
If no symptoms Symptom dependent
Acute onset
(<48 h)
If no risk of ODS
≤10 mmol/L per
24 h ≤18 mmol/L
per 48 h If risk of
ODS <8 mmol/L
per 24 h
≤8? 12 mmol/L per
24 h ≤18 mmol/L per
48 h
<12 mmol/L
per 24 h
If no risk of ODS
≤10 mmol/L per 24 h
≤18 mmol/L per 48 h
If risk of ODS <8 mmol/L
per 24 h
≤10 mmol/L first
24 h ≤8 mmol/L
every 24 h thereafter
≤10 mmol/L
per 24 h
No limits ≤8 mmol/L per 24 h
after seizures resolve,
Independent of onset
Chronic onset
(>48 h)
<8 mmol/L
per 24 h
≤8? 12 mmol/L
per 24 h ≤18 mmol/L
per 48 h
<12 mmol/L
per 24 h
<8? 12 mmol/L
per 24 h <18 mmol/L
per 48 h
≤10 mmol/L first
24 h ≤8 mmol/L
every 24 h thereafter
≤10 mmol/L
per 24 h
<8? 12 mmol/L
per 24 h <18 mmol/L
per 48 h
[Na] ? Serum sodium concentration.
NIV, Nederlandse Internisten Vereniging [16]; NHS, National Health Service [17]; GAIN, Guidelines and Audit Implementation Network [22]; AEEH, La Asociaci?n Espa?ola para el Estudio del H?gado [ 23]; EHN, European
Hyponatremia Network [25]; ERBP, European Renal Best Practice; ESE, European Society of Endocrinology; ESICM, European Society of Intensive Care Medicine [20]; UF, University of Florida [18]; HEP, Hyponatremia
Expert Panel [19]; RCH Melbourne, the Royal Children ? s Hospital Melbourne [21]; EAH-ICD, International Exercise-Associated Hyponatremia Consensus Development Conference [24].
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low level of evidence, while none were based on a high
level of evidence. The lack of high quality evidence may
have increased the part opinion had to play in framing
the recommendations. In addition, the evidence that
was available may have been interpreted differently
dependent on the importance for decision making given
to certain outcomes (e.g., serum sodium concentration).
Finally, differences in personal experience due to differ-
ing availability of medications may partly explain pos-
sible differences in perception of uncertainties around
drug safety.
However, it is also possible that discrepancies between
guidance documents may in part be explained by differ-
ences in underlying methods of development. Quality,
as assessed by AGREE II, was suboptimal at best, with
only two documents obtaining a score >50% for each of
the six quality domains [16,20]. The findings suggest
that several aspects related to methodological rigor of
development, stakeholder involvement, applicability, and
editorial independence could be improved, possibly im-
proving consistency in provided guidance. This is in line
with the findings of a recent overview of 42 appraisal
studies including a total of 626 clinical practice guidelines
across several clinical disciplines [26]. For guidelines to
be trustworthy, they must be i) founded on high quality
systematic reviews, ii) include the relevant stakeholders,
and iii) be applicable in clinical practice [9].
Only half of the guidance groups stated they had con-
ducted a systematic review of the evidence. Save one, the
reviews would not have met the Institute of Medicine? s cri-
teria for reporting high-quality systematic reviews [20,27],
because key methods for finding and assessing individual
studies as well as synthesizing the body of evidence were
not described. Conducting high-quality systematic reviews
requires specific methodological expertise and support
which may not be available to most groups [27]. One
solution might be to harmonize effort across organiza-
tions, thus focusing resources, allowing higher quality
reviews and reducing duplication and possibly inconsist-
ency between guidelines.
Six groups included healthcare professionals from dif-
ferent specialties [16,18,20,22,24,25]. Multidisciplinary
contribution serves to broaden the approach to health-care
problems, increase the completeness of evidence-finding
strategies, and help to identify hurdles to implementation.
When reflecting on approaches to hyponatremia, bringing
together several disciplines mirrors the clinical reality
of multiple specialty areas dealing with the same prob-
lem but looking at it from a different angle. Only one
of the development groups reported considering patients?
views and experiences, but even then did so to a limited
extent [20]. Decisions on clinical care should factor in
patient values and preferences. Interventions for chronichyponatremia, such as fluid restriction, may affect quality
of life and patient preference should influence the ultimate
recommendations.
Low scores for applicability mostly reflect the absence
of describing barriers to guideline implementation and
failure to provide tools for putting the recommendations
into practice. In part, guidelines are designed to deal with
the challenges of increasing knowledge and time-pressure.
They are designed to help make decisions at the point
of care. However, being often lengthy publications with-
out layered presentation of information, it is likely that
the majority of the guidance documents may not reach
their target audience or stimulate implementation. Four
guidance documents provided algorithms for diagnosis
or treatment [16,18,20,25]; although these are likely to
increase the utility of a guideline, it is unclear to what
extent they truly improve implementation of the recom-
mendations. How to best communicate evidence-based
recommendations to the relevant stakeholders is a recent
but active area of research lead by the DECIDE consor-
tium [28]. With results of their research expected, guide-
line developers will have additional targets for improving
the applicability in the future.
To our knowledge, this is the first attempt to systemat-
ically synthesize and appraise clinical guidelines on the
diagnosis and treatment of hyponatremia In accordance
with the Prisma statement, we conducted a comprehensive
literature search and searched an additional 337 web-
sites of specialist societies and guideline organizations
[29] (Additional file 6). We used AGREE II, a validated and
reliable instrument, and an adequate number of reviewers
to individually appraise the guidance documents [30]. On
top of the individual appraisals, we included an attempt
to resolve major discrepancies and increase consistency
by introducing an audiotaped group consensus meeting.
During this meeting, reviewers could explain and motivate
their scores and adapt them if they wanted to. This mostly
resulted only in modest downgrading of domain scores
by 1% to 10%. Most of the changes happened because
reviewers felt they had scored inconsistently for a same
rationale, or because they missed information during
the initial appraisal that was in fact available in the
document. Although the scores did not change substan-
tially, the group felt the discussion further highlighted
the qualitative differences between the guidance docu-
ments. In addition, even the reviewers with large devia-
tions from the mean in their initial scores felt they agreed
with the conclusion. It means that final average scores
were truly a product of consensus rather than a mathem-
atical calculation, as proposed in the original AGREE
protocol. We believe that a consensus meeting is valuable
in any guideline appraisal process, and particularly useful
if reviewer groups have the intention to select a guideline
for local use.
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http://www.biomedcentral.com/1741-7015/12/231This study has its limitations. We based our assessment
on what guideline organizations actually reported. Report-
ing by guideline developers may not wholly reflect what
occurred in practice with respect to the AGREE criteria,
and we did not seek additional clarification. However,
contacting guideline developers is not standard practice
when using AGREE as the instrument specifically aims to
provide a framework for assessing the quality of reporting
of recommendations. We aimed to summarize the existing
recommendations on diagnosis and treatment of hypona-
tremia as formulated by other guideline development
groups and to evaluate the quality of the guideline devel-
opment process. We did not aim to summarize or critic-
ally appraise the evidence base itself. Consequently, it is
difficult to assess to what extent differences between guid-
ance documents stem from differences in development
procedures rather than important limitations in the evi-
dence base that underpin individual recommendations.
Secondly, the purpose of using the AGREE instrument
was not to accuse guideline development groups of being
biased, but rather to highlight both strengths and weak-
nesses of existing guidance to suggest on how we could
make improvements in the future.
Calculation of summary scores for each domain across
reviewers required summing up all the scores of the in-
dividual items in a domain for each reviewer and then
standardizing this total as a percentage of the maximum
possible score for that domain. In doing so, the originally
semi-qualitative Likert scale was converted to a quantita-
tive score. This may have introduced numeric differences
between the guidance documents that were beyond the
discriminatory ability of the tool and possibly negligible in
practice. Finally, we acknowledge that four of the authors
of this paper also authored one of the guidelines included
in this review. Although we aimed to judge all guidance
documents fairly against the criteria outlined by the
AGREE instrument, we cannot rule out that a subcon-
scious intellectual competing interest unduly influenced
the scoring.Conclusions
Current guidelines on the assessment and treatment of
hyponatremia often fail to meet methodological criteria
for development and reporting as described by AGREE II.
Despite many similarities, recommendations are some-
times inconsistent, but to what extent this is attributable
to the underlying development process remains unclear.Additional files
Additional file 1: Table S1. Search strategies.
Additional file 2: Table S2. Data extraction template.Additional file 3: Table S3. Structure and content of the AGREE
instrument.
Additional file 4: Table S4. Table of excluded studies.
Additional file 5: Table S5. Mean scores across reviewers for the
individual AGREE II domain items.
Additional file 6: PRISMA checklist.
Abbreviation
AGREE II: Appraisal of guidelines for research and evaluation II.
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